Scientists test new eczema Drug's hidden effects on common medicines
NCT ID NCT05891119
Summary
This early study aimed to understand how a new eczema drug called rocatinlimab might affect how the body processes other common medications. Researchers enrolled 21 adults with moderate to severe atopic dermatitis to measure drug levels in the blood when rocatinlimab was taken alongside several standard drugs. The main goal was to check for safe interactions, not to treat the eczema itself.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Accel Research Sites (ACR)
DeLand, Florida, 32720-3134, United States
-
Axis Clinicals, LCC
Dilworth, Minnesota, 56529, United States
-
DermDox Dermatology Centers, PC - Camp Hill
Camp Hill, Pennsylvania, 17011, United States
-
DermDox Dermatology Centers, PC - Sugarloaf
Nashville, Tennessee, 37203-1632, United States
-
Direct Helpers Research Center (DHRC)
Hialeah, Florida, 33012-3618, United States
-
Velocity Clinical Research -Spartanburg
Spartanburg, South Carolina, 29303-4225, United States
-
Velocity Clinical Research, North Hollywood
North Hollywood, California, 91606-1570, United States
Conditions
Explore the condition pages connected to this study.